CAMBRIDGE, Mass.--(BUSINESS WIRE)--Nov. 20, 2018--
announced today that Aoife Brennan, M.B., B.Ch., Synlogic’s president
and chief executive officer, will provide a corporate update at the 30th
Annual Piper Jaffray Healthcare Conference at 8:30 am ET on Wednesday,
November 28, 2018, in New York City.
A live webcast of the presentation can be accessed under “Event
Calendar” in the Investors & Media section of the Company’s website.
An archived webcast recording will be available on the Synlogic website
for approximately 30 days after the event.
Synlogic is pioneering the development of a novel class of living
medicines, Synthetic Biotic medicines, based on its proprietary drug
development platform. Synlogic leverages the tools and principles of
synthetic biology to genetically engineer beneficial microbes to perform
or deliver critical functions missing or damaged due to disease.
Synthetic Biotic medicines are designed to act locally and have a
systemic effect to address disease in patients. Synlogic’s two lead
programs, SYNB1020 and SYNB1618, are orally administered and target
hyperammonemia as a result of liver damage or genetic disease, and
phenylketonuria, respectively. Synlogic is also developing SYNB1891 as
an intratumorally administered Synthetic Biotic medicine for the
treatment of cancer. In addition, the company is leveraging the broad
potential of its platform to create additional Synthetic Biotic
medicines for the treatment of liver disease, as well as inflammatory
and immune disorders, including Synlogic’s collaboration with AbbVie to
develop Synthetic Biotic-based treatments for inflammatory bowel disease
(IBD). For more information, please visit www.synlogictx.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20181120005025/en/